This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aortic valve disease.
4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heartdisease, has been granted Breakthrough Device designation by the U.S. Food and Drug Administratio n ( FDA ) for the AltaValve System , a transcatheter mitral valve replacement (TMVR) device.
Valvular heartdisease is a common cause of morbidity and mortality worldwide and has no effective medical therapy. Severe disease is managed with valve replacement procedures, which entail high health care–related costs and postprocedural morbidity and mortality. Circulation, Ahead of Print.
BackgroundIdentification of children with latent rheumatic heartdisease (RHD) by echocardiography, before onset of symptoms, provides an opportunity to initiate secondary prophylaxis and prevent disease progression. Echocardiograms were independently reviewed by an expert adjudication panel. parasternal long axis).
Objective This study aims to assess the ability of state-of-the-art machine learning algorithms to detect valvular heartdisease (VHD) from digital heart sound recordings in a general population that includes asymptomatic cases and intermediate stages of disease progression.
a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that surgeons have successfully performed the world’s first mitral valve replacement using the Made in India, SSi Mantra Surgical Robotic System. from 2022 to 2031.
1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aortic valve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. tim.hodson Wed, 09/04/2024 - 15:53 Sept.
Getty Images milla1cf Tue, 01/16/2024 - 14:11 January 16, 2024 — Artificial intelligence (AI) has the potential to detect rheumatic heartdisease (RHD) with the same accuracy as a cardiologist, according to new research demonstrating how sophisticated deep learning technology can be applied to this disease of inequity.
These key takeaways from the research letter on IVL-facilitated valvuloplasty for severely calcified mitral valve stenosis are published in the Journal of the American College of Cardiology (JACC) Cardiovascular Interventions. an interventional cardiologist and structural heartdisease expert at Henry Ford Health. “We
Abstract Worldwide, valvular heartdisease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock.
Valvular heartdisease (VHD) has been a significant health problem, particularly in developed countries, in relation to the aging population. Recent developments in the management of VHD require a more accurate assessment of disease severity to determine the need for transcatheter interventions or open heart surgery.
In these panel discussions, host Andrea Price MS, AACC brings together Bailey Estes MSN, AGNP-C, Nicole Dellise, NP, and Kristen deAlmeida, PharmD to explore best practices related to structural heartdisease. In this episode, the focus is on mitral valve disease.
Despite being a leading cause of morbidity and mortality among young people, affecting predominantly women, rheumatic heartdisease (RHD) remains neglected and understudied. While RHD has been nearly eradicated in high-income countries, it continues to be a significant and active health issue in low- and middle-income countries.
Many patients with symptoms of mitral regurgitation are not candidates for open heart surgery due to their advanced age or competing comorbidities, nor are they candidates for the only alternative, the MitraClip device. Your heart has four valves that move blood in and out of its four chambers.
22, 2025More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association 2025 HeartDisease and Stroke Statistical Update. tim.hodson Tue, 03/04/2025 - 14:11 Feb.
Webinar STS South Asia Webinar in collaboration with IACTS : Rheumatic Mitral Valve Repair gmckinney Fri, 10/18/2024 - 10:43 November 9, 2024 The first session of the South Asia webinar series delves into valve repair strategies for rheumatic mitral valve disease. Moderators Vinod H.
Webinar Rheumatic Mitral Valve Repair: STS South Asia Webinar in collaboration with IACTS gmckinney Fri, 10/18/2024 - 10:43 November 9, 2024 The first session of the South Asia webinar series delves into valve repair strategies for rheumatic mitral valve disease.
The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.
On May, 25th 2018 (coinciding with Global Surgery Day), the World Health Organization (WHO) and its Member States unanimously accepted the Global Resolution on Rheumatic Fever and Rheumatic HeartDisease (RHD) at the World Health Assembly in Geneva, Switzerland. In these, case-fatality rates are as high as 5%.
Sudden breathlessness at night in those with known heartdisease is usually due to collection of fluid in the lungs (pulmonary edema). Extra fluid in the body can occur due to failure of heart, kidneys, liver and rarely due to other causes.
Mitral valve failure is one of the most common valvular heartdiseases worldwide. Valve replacement and repair have an impact on the quality of life of patients. Therefore, the present study was conducted to c.
BackgroundRheumatic mitral stenosis (RMS) is a common valvular heartdisease in developing countries. We sought to evaluate the early experience of patients with RMS undergoing transcatheter mitral valve replacement (TMVR).MethodsIn MethodsIn this retrospective study, a total of 5 RMS patients accepted TMVR.
It’s a celebration of the amazing innovation that has occurred in structural heartdisease therapy over the last 20 years and I’m proud to be part of it. “Andreas Grüntzig was a pioneer in the field, so I’m grateful and honored to receive the Ethica Award,” said Dr. St.
The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first transcatheter aortic valve replacement (TAVR) in 2002, as well as the first transcatheter mitral commissurotomy in 1995 and the first balloon aortic valvuloplasty in 1986. He passed away Feb. 16, 2024 at the age of 79.
Pathogeneses include connective tissue disorders, smooth muscle contraction disorders, and congenital heartdisease, including bicuspid aortic valve, among others. The American Heart Association has published guidelines for diagnosis and management of thoracic aortic disease.
Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heartdisease in Europe. Abstract Aims Tricuspid regurgitation (TR) is commonly observed in patients with severe left-sided valvular heartdisease (VHD).
Journal of the American Heart Association, Ahead of Print. BackgroundValvular heartdisease (VHD) is a major focus of cardiovascular medicine, but limited data are available for racial and ethnic minorities. In people aged 75 years, tricuspid and mitral regurgitation were the most prevalent VHD (21.1%
Objective Pulmonary hypertension (PHT) commonly coexists with significant mitral regurgitation (MR), but its prevalence and prognostic importance have not been well characterised. In a large cohort of adults with moderate or greater MR, we aimed to describe the prevalence and severity of PHT and assess its influence on outcomes.
Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. BackgroundValvular heartdisease poses an escalating global health challenge with an increasing impact on mortality and disability. cases of rheumatic heartdisease, 13.3 In 2021, an estimated 54.8 million (95% UI, 11.415.2)
Attendees can join with their peers and participate in sessions on structural heartdisease, congenital heartdisease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heartdisease, debates and games and early career topics.
Multi-valve The STS used contemporary national data from the STS Adult Cardiac Surgery Database between July 2017 and December 2023 to analyze outcomes of 32,938 patients who underwent multi-valve surgery involving replacement of the aortic valve, plus replacement or repair of the mitral valve with and without concomitant CABG.
We know that structural heartdisease and heart failure are the leading causes of hospitalization and morbidity in the U.S. This milestone makes AISAP the first company in the world to secure FDA clearance in the CADx pathway for the comprehensive diagnosis of structural heartdiseases using POCUS.
Henry Ford Health's Center for Structural HeartDisease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Medical Director of Structural HeartDisease at Henry Ford Health. “We
“Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heartdisease,” said Daveen Chopra , Edwards’ corporate vice president, transcatheter mitral and tricuspid therapies. “We
to 2.94), increased ratio of early transmitral flow velocity to early mitral annular velocity (>24, HR=1.79, 95% CI 1.11 Conclusion In HFmrEF patients with ischaemic heartdisease, admission LUS-BL>11 is independently associated with an increased risk of CV event at 90 days following discharge.
Background The burden of valvular heartdisease (VHD) has increased significantly among ageing populations, yet remains poorly understood in the present-day context of percutaneous and surgical interventions. Clinical correlates of VHD included demographics, coronary artery disease, heart failure and atrial fibrillation.
The heart has four valves (aortic, mitral, pulmonic, and tricuspid) that open and close to move blood through the heart and to the rest of the body. If a valve cannot open or close fully it can interfere with blood flow and cause a host of health issues, including heart attack and stroke. and affects an estimated 1.6
Atrial functional mitral regurgitation (AFMR) is a common type of MR linked to high rates of heart failure, highlighting the need to understand its prognostic factors.
Objective A substantial proportion of patients with rheumatic heartdisease (RHD) have tricuspid regurgitation (TR). This study aimed to identify the impact of functional TR on clinical outcomes and predictors of progression in a large population of patients with RHD.
“Until now, there was no available transcatheter treatment options for patients with tricuspid valve disease,” said Robert Kipperman, MD , interventional cardiologist and structural heartdisease specialist at Gagnon Cardiovascular Institute’s Valve Center at Morristown Medical Center , part of Atlantic Health System. “We
approval of TriClip is a significant advancement for people suffering from tricuspid regurgitation, a heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D. , the Roger L. and Lynn C. important safety information on TriClip, visit [link].
His impressive international academic collaborations include the establishment of multiple global registries and the training of heart teams in structural heart imaging and procedures worldwide.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content